Skip to main navigation Skip to search Skip to main content

Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

  • John Pagel
  • , Franck Morschhauser
  • , Tilly Herve
  • , Aristeidis Chaidos
  • , Tycel Phillips
  • , Vincent Ribrag
  • , Phillip Campbell
  • , Christophe Fruchart
  • , Wojciech Jurczak
  • , Pamela McKay
  • , Stephen Opat
  • , John Radford
  • , Alice McDonald
  • , Haley Howell
  • , Kate Newberry
  • , Mark Woodruff
  • , Alicia Clawson
  • , John Larus
  • , Stephen Blakemore
  • , Harry Miao
  • Gilles Salles

Research output: Contribution to journal › Article › peer-review

Original languageAmerican English
JournalClinical Lymphoma, Myeloma Leukemia
Volume18
DOIs
StatePublished - Sep 1 2018

Disciplines

  • Medicine and Health Sciences
  • Oncology
  • Pathology
  • Internal Medicine

Cite this